456

Compound name
Alpelisib
Alt Name
BYL-719
BYL719
Piqray
Compound Image
Alpelisib.png
SMILES
CC1=C(SC(=N1)NC(=O)N2CCCC2C(=O)N)C3=CC(=NC=C3)C(C)(C)C(F)(F)F
MW
441.50
Brutto
C19H22F3N5O2S
InChI
InChI=1S/C19H22F3N5O2S/c1-10-14(11-6-7-24-13(9-11)18(2,3)19(20,21)22)30-16(25-10)26-17(29)27-8-4-5-12(27)15(23)28/h6-7,9,12H,4-5,8H2,1-3H3,(H2,23,28)(H,25,26,29)/t12-/m0/s1
InChI Key
STUWGJZDJHPWGZ-LBPRGKRZSA-N
Approval Jurisdiction
2019 FDA
Approved for clinical use
Breast Cancer, HR+Ve, HER2-Ve
CAS
1217486-61-7
PubChem CID
56649450
Action
PI3Kα
Approved Drug List
1
Commercial Vendor
Novartis